| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Over the last 12 months, insiders at Evotec SE have bought $0 and sold $0 worth of Evotec SE stock.
On average, over the past 5 years, insiders at Evotec SE have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 392 shares for transaction amount of $5,023 was made by BANK OF AMERICA CORP /DE/ (10 percent owner) on 2011‑10‑18.
| 2011-10-18 | Sale | BANK OF AMERICA CORP /DE/ | 10 percent owner | 392 0.0003% | $12.75 | $4,999 | +2.53% | |
| 2011-10-18 | BANK OF AMERICA CORP /DE/ | 10 percent owner | 392 0.0003% | $12.81 | $5,023 | +2.53% |
| Increased Positions | 24 | +44.44% | 2M | +16.08% |
| Decreased Positions | 22 | -40.74% | 2M | -15.84% |
| New Positions | 18 | New | 531,853 | New |
| Sold Out Positions | 11 | Sold Out | 85,430 | Sold Out |
| Total Postitions | 56 | +3.7% | 10M | +0.24% |
| Mubadala Investment Co Pjsc | $14,621.00 | 1.29% | 4.6M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $4,547.00 | 0.4% | 1.43M | +224,345 | +18.61% | 2025-09-30 |
| Blackrock, Inc. | $4,134.00 | 0.37% | 1.3M | -40,263 | -3% | 2025-09-30 |
| Dcf Advisers, Llc | $3,813.00 | 0.34% | 1.2M | +84,500 | +7.58% | 2025-09-30 |
| Morgan Stanley | $1,001.00 | 0.09% | 314,912 | -70,302 | -18.25% | 2025-09-30 |
| Wcm Investment Management, Llc | $955.00 | 0.08% | 300,277 | +2,370 | +0.8% | 2025-09-30 |
| Pitcairn Co | $514.00 | 0.05% | 161,769 | -99,412 | -38.06% | 2025-09-30 |
| Abc Arbitrage Sa | $420.00 | 0.04% | 132,057 | +93,097 | +238.96% | 2025-09-30 |
| Citadel Advisors Llc | $305.00 | 0.03% | 96,045 | +62,471 | +186.07% | 2025-09-30 |
| Envestnet Asset Management Inc | $241.00 | 0.02% | 75,711 | -15,953 | -17.4% | 2025-09-30 |